Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Learning About Advanced Cutaneous Squamous Cell Carcinoma
November 19th 2020In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Ezra Cohen and two patients with advanced cutaneous squamous cell carcinoma about the disease, its treatments and their recommendations for others.
Read More
Expert Shines Light on Early Detection Options for Those at Increased Risk for Pancreatic Cancer
November 10th 2020On behalf of the National Pancreas Foundation, Dr. Diane Simeone offers insight into early detection options for those at increased risk of pancreatic cancer, including surveillance and screening.
Read More
Katie Couric and Paula Schneider: Sharing Cancer Journeys One Letter At a Time
October 29th 2020In this episode of the “CURE Talks Cancer” podcast, we spoke with television journalist Katie Couric and Susan G. Komen CEO Paula Schneider about their experiences with cancer, and the advice they offered their pre-cancer selves.
Read More
FDA Grants Regular Approval to Venclexta Combo for Untreated Acute Myeloid Leukemia
October 16th 2020After granting accelerated approval in 2018, the Food and Drug Administration approved Venclexta in combination with Vidaza, Dacogen or low dose cytarabine in newly diagnosed patients with AML.
Read More
Cabometyx-Tecentriq Combo Shows Promise in Advanced Kidney Cancer
October 5th 2020“The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” Dr. Sumanta Kumar Pal, co-director of the Kidney Cancer Program at City of Hope in California, said during a presentation of the clear cell renal cell carcinoma cohort.
Read More
Phase 2 Study of VERU-111 in Prostate Cancer Subgroup Completes Patient Enrollment
September 30th 2020VERU Inc. announced it has completed enrollment of 40 men with metastatic prostate cancer who have become resistant to at least one androgen receptor targeting agent for its phase 2 study of VERU-111.
Read More
Lynparza Significantly Improves Survival in Subset of Patients with Metastatic Prostate Cancer
September 23rd 2020The PARP inhibitor Lynparza reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer compared with Xtandi or Zytiga plus the corticosteroid prednisone.
Read More